Table 1.
Baseline patient characteristics for pooled analysis and DURATION‐6
| Pooled analysis 1 (N = 1223) | DURATION‐6 (N = 911) | |||
|---|---|---|---|---|
| Exenatide once weekly (n = 617) | Exenatide twice daily (n = 606) | Exenatide once weekly (n = 461) | Liraglutide (n = 450) | |
| Age, years | 55 ± 11 | 56 ± 10 | 56 ± 9 | 56 ± 10 |
| Men, n (%) | 342 (55) | 326 (54) | 254 (55) | 245 (54) |
| Race/ethnicity, n (%) | ||||
| White | 204 (33) | 173 (29) | 304 (66) | 287 (64) |
| Asian | 345 (56) | 344 (57) | 55 (12) | 56 (12) |
| Hispanic | 53 (9) | 61 (10) | 98 (21) | 99 (22) |
| Black | 15 (2) | 28 (5) | 3 (1) | 3 (1) |
| Other | 0 | 0 | 1 (<1) | 4 (1) |
| Body weight, kg | 83 ± 22 | 83 ± 21 | 91 ± 19 | 91 ± 19 |
| BMI, kg/m2 | 30 ± 6 | 30 ± 6 | 32 ± 6 | 32 ± 5 |
| HbA1c, % | 8.5 ± 1.1 | 8.5 ± 1.1 | 8.4 ± 1.0 | 8.4 ± 1.0 |
| FPG, mmol/L | 9.2 ± 2.5 | 9.2 ± 2.6 | 9.6 ± 2.5 | 9.8 ± 2.6 |
| Duration of T2D, years | 7 ± 5 | 8 ± 6 | 8 ± 6 | 9 ± 6 |
| Background metformin, n (%)2 | 506 (82) | 484 (80) | 436 (95) | 425 (94) |
Values are reported as mean ± s.d., unless otherwise stated.
Abbreviations: BMI, body mass index; FPG, fasting plasma glucose.
1
Studies included DURATION‐1, DURATION‐5 and NCT00917267.
2
Use of metformin alone or in combination with sulphonylurea, thiazolidinedione, insulin, or other glucose‐lowering therapy.